Scholarlink

Background <p>The analgesic efficacy of liposomal bupivacaine (LB) for transversus abdominis plane block (TAPB) in laparoscopic colorectal surgery (LCS) remains controversial. This trial aimed to determine whether LB provides better analgesia and recovery outcomes than ropivacaine for TAPB.</p> Methods <p>In this randomized, double-blind trial, 136 patients undergoing LCS were randomly allocated (1:1) to receive bilateral TAPB with either LB (266&#xa0;mg total, 133&#xa0;mg per side) or ropivacaine (0.375%, 20 mL per side). The primary outcome was the area under the curve (AUC) of the visual analogue scale (VAS) for movement-evoked pain (MEP) over 72&#xa0;h. Secondary outcomes included intraoperative remifentanil consumption, the AUC of VAS for pain at rest (PAR), International Pain Outcome Questionnaire (IPOQ) scores, and the incidence of chronic pain.</p> Results <p>Compared with ropivacaine, LB significantly reduced AUC of the VAS for MEP (median difference: -20.15; 95% CI: -33.25, -2.35; <i>P</i> = 0.001); intraoperative remifentanil consumption (-59.75&#xa0;µg; 95% CI: -142.00, -9.50; <i>P</i> = 0.001); sleep disturbance (-0.5; 95% CI: -1.0, 0; <i>P</i> = 0.002) and pain interference with out-of-bed activities (-1; 95% CI: -1, 0; <i>P</i> = 0.014). No significant intergroup differences were observed in the AUC of the VAS for PAR or chronic pain at 3 months.</p> Conclusions <p>In LCS patients, liposomal bupivacaine significantly reduces movement-evoked pain, improves intraoperative analgesia, enhances sleep quality, and alleviates pain-related interference with activity within 72&#xa0;h postoperatively. However, these benefits did not translate into a reduction in pain at rest or the incidence of chronic pain.</p> Trial registration <p>Chinese Clinical Trial Registry, ChiCTR2400082663. Registered on April 3, 2024.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reduced movement-evoked pain with liposomal bupivacaine versus ropivacaine in transversus abdominis plane block for laparoscopic colorectal surgery: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月17日

查看全文
  • Yanan Wang,
  • Leilei Dai,
  • Yu Liu,
  • Yanzhe Ba,
  • Zhihua Zhang,
  • Feng Qi,
  • Shaozhong Yang

摘要

Background

The analgesic efficacy of liposomal bupivacaine (LB) for transversus abdominis plane block (TAPB) in laparoscopic colorectal surgery (LCS) remains controversial. This trial aimed to determine whether LB provides better analgesia and recovery outcomes than ropivacaine for TAPB.

Methods

In this randomized, double-blind trial, 136 patients undergoing LCS were randomly allocated (1:1) to receive bilateral TAPB with either LB (266 mg total, 133 mg per side) or ropivacaine (0.375%, 20 mL per side). The primary outcome was the area under the curve (AUC) of the visual analogue scale (VAS) for movement-evoked pain (MEP) over 72 h. Secondary outcomes included intraoperative remifentanil consumption, the AUC of VAS for pain at rest (PAR), International Pain Outcome Questionnaire (IPOQ) scores, and the incidence of chronic pain.

Results

Compared with ropivacaine, LB significantly reduced AUC of the VAS for MEP (median difference: -20.15; 95% CI: -33.25, -2.35; P = 0.001); intraoperative remifentanil consumption (-59.75 µg; 95% CI: -142.00, -9.50; P = 0.001); sleep disturbance (-0.5; 95% CI: -1.0, 0; P = 0.002) and pain interference with out-of-bed activities (-1; 95% CI: -1, 0; P = 0.014). No significant intergroup differences were observed in the AUC of the VAS for PAR or chronic pain at 3 months.

Conclusions

In LCS patients, liposomal bupivacaine significantly reduces movement-evoked pain, improves intraoperative analgesia, enhances sleep quality, and alleviates pain-related interference with activity within 72 h postoperatively. However, these benefits did not translate into a reduction in pain at rest or the incidence of chronic pain.

Trial registration

Chinese Clinical Trial Registry, ChiCTR2400082663. Registered on April 3, 2024.

Graphical Abstract